Clinical outcome measures and their evidence base in degenerative cervical myelopathy: a systematic review to inform a core measurement set (AO Spine RECODE-DCM).
Authors
Bhatti, Aniqah
Dohle, Esmee
Furlan, Julio C
Fehlings, Michael G
Harrop, James S
Milligan, James
Sarewitz, Ellen
Curt, Armin
Rahimi-Movaghar, Vafa
Aarabi, Bizhan
Tetreault, Lindsay
Chen, Robert
Guest, James D
Kalsi-Ryan, Sukhvinder
Kotter, Mark
Davies, Benjamin
AO Spine RECODE-DCM Steering Committee
Publication Date
2022-01-19Journal Title
BMJ Open
ISSN
2044-6055
Publisher
BMJ
Volume
12
Issue
1
Language
en
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Yanez Touzet, A., Bhatti, A., Dohle, E., Bhatti, F., Lee, K. S., Furlan, J. C., Fehlings, M. G., et al. (2022). Clinical outcome measures and their evidence base in degenerative cervical myelopathy: a systematic review to inform a core measurement set (AO Spine RECODE-DCM).. BMJ Open, 12 (1) https://doi.org/10.1136/bmjopen-2021-057650
Description
Funder: AO Foundation; FundRef: http://dx.doi.org/10.13039/501100001702
Abstract
OBJECTIVES: To evaluate the measurement properties of outcome measures currently used in the assessment of degenerative cervical myelopathy (DCM) for clinical research. DESIGN: Systematic review DATA SOURCES: MEDLINE and EMBASE were searched through 4 August 2020. ELIGIBILITY CRITERIA: Primary clinical research published in English and whose primary purpose was to evaluate the measurement properties or clinically important differences of instruments used in DCM. DATA EXTRACTION AND SYNTHESIS: Psychometric properties and clinically important differences were both extracted from each study, assessed for risk of bias and presented in accordance with the Consensus-based Standards for the selection of health Measurement Instruments criteria. RESULTS: Twenty-nine outcome instruments were identified from 52 studies published between 1999 and 2020. They measured neuromuscular function (16 instruments), life impact (five instruments), pain (five instruments) and radiological scoring (five instruments). No instrument had evaluations for all 10 measurement properties and <50% had assessments for all three domains (ie, reliability, validity and responsiveness). There was a paucity of high-quality evidence. Notably, there were no studies that reported on structural validity and no high-quality evidence that discussed content validity. In this context, we identified nine instruments that are interpretable by clinicians: the arm and neck pain scores; the 12-item and 36-item short form health surveys; the Japanese Orthopaedic Association (JOA) score, modified JOA and JOA Cervical Myelopathy Evaluation Questionnaire; the neck disability index; and the visual analogue scale for pain. These include six scores with barriers to application and one score with insufficient criterion and construct validity. CONCLUSIONS: This review aggregates studies evaluating outcome measures used to assess patients with DCM. Overall, there is a need for a set of agreed tools to measure outcomes in DCM. These findings will be used to inform the development of a core measurement set as part of AO Spine RECODE-DCM.
Keywords
Neurology, 1506, 1713, degenerative cervical myelopathy, cervical spondylotic myelopathy, spinal cord compression, outcome measures, core measurement set
Identifiers
bmjopen-2021-057650
External DOI: https://doi.org/10.1136/bmjopen-2021-057650
This record's URL: https://www.repository.cam.ac.uk/handle/1810/333280
Rights
Licence:
http://creativecommons.org/licenses/by-nc/4.0/
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.